Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease
AbstractThe aim of the study was to determine the prevalence of anti-hepatitis A virus [anti-HAV] antibodies among 172 children with chronic liver disease, and to calculate the cost- effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years
El Karaksy, H., El Sayed, R., El Raziky, M., El Koofy,N. & Mansour, S. (2008). Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease. http://www.who.int/iris/handle/10665/117497
EMHJ - Eastern Mediterranean Health Journal, 14 (4), 804-809, 2008
MetadataShow full item record
Showing items related by title and MeSH subject.
Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection Sorkhi, H.; Roushan, M.R.H.; Al Hashemi, G.H.; Dooki, M.R.E.; Bai, S. (2008)The aim of this study was to determine the efficacy of hepatitis B virus [HBV] vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers [HBcAb, HBsAg and HBsAb]. Of 62 patients, 53 [85.5%] responded to vaccination and 26 [49.1%] were high responders. All individuals with ...